Skip to main content
Premium Trial:

Request an Annual Quote

SimBioSys, Mayo Clinic Partner to Develop AI Tools for Early Breast Cancer Decision Support

NEW YORK – SimBioSys on Tuesday said it signed a collaboration agreement with the Mayo Clinic to develop cloud-based clinical software tools to support personalized treatment decisions for patients with early-stage breast cancer.

Under the terms of the collaboration, SimBioSys will continue using artificial intelligence-based methods to analyze data from the Mayo Clinic's Breast Cancer Genome-Guided Therapy Study (BEAUTY). In the study, Mayo Clinic scientists are trying to understand why some breast cancer patients respond to standard neoadjuvant chemotherapy while others don't. Researchers are primarily interested in identifying cancer-associated genetic alterations, determining the frequency of known and targetable tumor alterations, developing xenograft cell lines for mechanistic and functional studies, and identifying mutations associated with pathologic complete response to therapy.

SimBioSys has developed a software tool using its cloud-based medical device platform TumorSight, which builds a custom three-dimensional model of a breast cancer patient's tumor that can help with surgical planning using magnetic resonance imaging data collected during the course of standard treatment.

In the present collaboration, SimBioSys will conduct simulations using previously acquired data from the trial to validate the platform and perform in silico scenario analysis guided by Mayo Clinic researchers. Chicago-based SimBioSys said the aim of the collaboration is to develop tools to help with decisions such as individualized surgical planning, treatment, drug selection, and risk stratification.